Revenue Interest Purchase Agreement - Additional Information (Details) - Purchase Agreement - OrbiMed - USD ($)		12 Months Ended
	Sep. 12, 2022	Dec. 31, 2023	Dec. 31, 2022	Sep. 12, 2024	Mar. 12, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received	$ 125,000,000
Potential revenue interest second payment to be received	$ 75,000,000
Purchase agreement, second payment date	Sep. 12, 2025
Potential revenue interest third payment to be received	$ 50,000,000
Purchase agreement, third payment date	Sep. 12, 2025
Revenue interest payment term	45 days
Percentage of revenue interest payments	100.00%
Percentage of cumulative purchaser payments	165.00%
Cumulative purchaser payments repayment date	Sep. 12, 2032
Increase in return cap percentage of cumulative purchaser payments	175.00%
Amortization of purchase agreement obligation		$ 0
Effective interest rate		9.20%
Debt issuance costs		$ 600,000
Revenue interest payable		$ 2,275,000	$ 2,760,000
Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of cumulative purchaser payments				125.00%	120.00%
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue interest payment to be received	$ 125,000,000